US equities |
MU $913.52 ▲+4.10% TSLA $394.19 ▲+5.90% NVDA $216.30 ▲+2.53% SPCX $148.74 ▲+0.84% META $634.66 ▼-1.24% AAPL $343.34 ▼-1.26% SNDK $1,273.07 ▲+2.83% INTC $91.76 ▲+5.52%
FinancialContent

Articles published by Pathos AI

News headline image
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
From Pathos AI
Via Business Wire
Tickers BMY TEM
News headline image
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic
From Pathos AI
Via Business Wire
News headline image
Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC
From Pathos AI
Via Business Wire
News headline image
Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform
From Pathos AI
Via GlobeNewswire
News headline image
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
From Pathos AI
Via GlobeNewswire
News headline image
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
From Pathos AI
Via GlobeNewswire
News headline image
Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor
From Pathos AI
Via GlobeNewswire
News headline image
Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development
From Pathos AI
Via GlobeNewswire
News headline image
Pathos Expands Pipeline With Worldwide License of Phase 2-ready Brain-penetrant, PRMT5 Inhibitor
From Pathos AI
Via GlobeNewswire